enGene Holdings Inc. (NASDAQ:ENGN – Get Free Report) saw a large decline in short interest in the month of February. As of February 28th, there was short interest totalling 60,300 shares, a decline of 31.9% from the February 13th total of 88,500 shares. Based on an average daily volume of 131,100 shares, the days-to-cover ratio is currently 0.5 days. Currently, 0.3% of the company’s stock are short sold.
enGene Price Performance
Shares of NASDAQ ENGN traded up $0.05 during mid-day trading on Friday, hitting $5.40. 23,426 shares of the stock traded hands, compared to its average volume of 131,979. The company has a debt-to-equity ratio of 0.08, a current ratio of 16.87 and a quick ratio of 16.87. enGene has a twelve month low of $4.42 and a twelve month high of $18.40. The company has a market cap of $275.28 million, a PE ratio of -9.31 and a beta of -0.61. The firm has a 50 day simple moving average of $6.51 and a two-hundred day simple moving average of $7.12.
enGene (NASDAQ:ENGN – Get Free Report) last announced its earnings results on Thursday, December 19th. The company reported ($0.34) EPS for the quarter, topping the consensus estimate of ($0.40) by $0.06. As a group, equities research analysts forecast that enGene will post -1.56 EPS for the current fiscal year.
Analyst Ratings Changes
View Our Latest Stock Analysis on ENGN
Institutional Trading of enGene
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Franklin Resources Inc. increased its position in enGene by 48.7% in the 3rd quarter. Franklin Resources Inc. now owns 1,189,952 shares of the company’s stock valued at $7,854,000 after buying an additional 389,918 shares in the last quarter. Point72 Asset Management L.P. increased its position in enGene by 1,410.3% in the 3rd quarter. Point72 Asset Management L.P. now owns 663,000 shares of the company’s stock valued at $4,376,000 after buying an additional 619,100 shares in the last quarter. Vontobel Holding Ltd. bought a new stake in enGene in the 4th quarter valued at about $69,000. Wolverine Asset Management LLC acquired a new position in enGene during the 3rd quarter valued at about $37,000. Finally, Cubist Systematic Strategies LLC boosted its stake in enGene by 15.7% during the 4th quarter. Cubist Systematic Strategies LLC now owns 15,342 shares of the company’s stock valued at $102,000 after purchasing an additional 2,080 shares during the last quarter. 64.16% of the stock is owned by institutional investors.
enGene Company Profile
enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.
Read More
- Five stocks we like better than enGene
- Insider Buying Explained: What Investors Need to Know
- How to Build the Ultimate Everything ETF Portfolio
- How to Short a Stock in 5 Easy Steps
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- Insider Selling Explained: Can it Inform Your Investing Choices?
- 3 Stocks With High ROE and Market-Beating Growth Potential
Receive News & Ratings for enGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for enGene and related companies with MarketBeat.com's FREE daily email newsletter.